EP0905143A3 - Komplexe von menschlichen Wachstumhormon und Zink und Verwendung - Google Patents

Komplexe von menschlichen Wachstumhormon und Zink und Verwendung Download PDF

Info

Publication number
EP0905143A3
EP0905143A3 EP98307646A EP98307646A EP0905143A3 EP 0905143 A3 EP0905143 A3 EP 0905143A3 EP 98307646 A EP98307646 A EP 98307646A EP 98307646 A EP98307646 A EP 98307646A EP 0905143 A3 EP0905143 A3 EP 0905143A3
Authority
EP
European Patent Office
Prior art keywords
growth hormone
human growth
zinc
complex
sustained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98307646A
Other languages
English (en)
French (fr)
Other versions
EP0905143A2 (de
Inventor
Yutaka Yamagata
Masafumi Misaki
Susumu Iwasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of EP0905143A2 publication Critical patent/EP0905143A2/de
Publication of EP0905143A3 publication Critical patent/EP0905143A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/839Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98307646A 1997-09-26 1998-09-21 Komplexe von menschlichen Wachstumhormon und Zink und Verwendung Withdrawn EP0905143A3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26125197 1997-09-26
JP26125197 1997-09-26
JP261251/97 1997-09-26

Publications (2)

Publication Number Publication Date
EP0905143A2 EP0905143A2 (de) 1999-03-31
EP0905143A3 true EP0905143A3 (de) 2000-09-06

Family

ID=17359239

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98307646A Withdrawn EP0905143A3 (de) 1997-09-26 1998-09-21 Komplexe von menschlichen Wachstumhormon und Zink und Verwendung

Country Status (3)

Country Link
US (2) US6191107B1 (de)
EP (1) EP0905143A3 (de)
CA (1) CA2248390A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191107B1 (en) * 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
WO2001021187A1 (en) * 1999-09-17 2001-03-29 Takeda Chemical Industries, Ltd. Process for producing protein powder
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4361710B2 (ja) 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
TWI283182B (en) * 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
DK1372729T3 (da) * 2001-02-23 2009-06-22 Genentech Inc Nedbrydelige polymere til injektion
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
BRPI0418304A (pt) * 2004-01-07 2007-05-02 Trimeris Inc peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
US20060183956A1 (en) * 2004-12-17 2006-08-17 Uxb Method of transporting waste explosive materials
US7456251B2 (en) * 2006-02-02 2008-11-25 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
BRPI0809995A2 (pt) * 2007-04-03 2015-07-21 Trimeris Inc Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv
KR20100080812A (ko) * 2007-09-25 2010-07-12 트라이머리스, 인코퍼레이티드 치료용 항-hiv 펩티드의 합성 방법
WO2009057808A1 (ja) * 2007-11-02 2009-05-07 Aspion Co., Ltd. 難溶性薬物-界面活性剤複合体製品とその製造法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216485A1 (de) * 1985-08-12 1987-04-01 International Minerals And Chemical Corporation Verzögerte Wirkstoffabgabe von wachstumsfördernden Hormonen
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
WO1996007399A1 (en) * 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
WO1996040074A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
WO1996040072A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
WO1997001331A2 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
WO1997003692A1 (en) * 1995-07-14 1997-02-06 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
WO1994012158A1 (en) * 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US6191107B1 (en) * 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216485A1 (de) * 1985-08-12 1987-04-01 International Minerals And Chemical Corporation Verzögerte Wirkstoffabgabe von wachstumsfördernden Hormonen
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
WO1996007399A1 (en) * 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
WO1996040074A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
WO1996040072A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
WO1997001331A2 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
WO1997003692A1 (en) * 1995-07-14 1997-02-06 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Also Published As

Publication number Publication date
CA2248390A1 (en) 1999-03-26
US20010002263A1 (en) 2001-05-31
US6191107B1 (en) 2001-02-20
US6429296B2 (en) 2002-08-06
EP0905143A2 (de) 1999-03-31

Similar Documents

Publication Publication Date Title
AU2684497A (en) Biodegradable sustained-release preparation, biodegradable pheromone dispenser and biodegradable pest controlling agent
EP0905143A3 (de) Komplexe von menschlichen Wachstumhormon und Zink und Verwendung
EP1090640A3 (de) Formulierungen mit Insulin-Analogen
CA2311696A1 (en) Self-tanning composition comprising carmine
CA2151564A1 (en) Monomeric insulin analog formulations
HUP9601555A3 (en) Pesticidal microcapsule compositions, preparation and use thereof
AU6020494A (en) Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0635241A3 (de) Bioverträgliche Klammer für Nahtknoten.
AU6254498A (en) Polyesteramide, its preparation and surgical devices fabricated therefrom
AU4913699A (en) Biocompatible polymers, preparation method and compositions containing same
IL123393A0 (en) Pesticide compositions comprising redispersible polymers
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
EP0601883A3 (de) Klebene Silikonkautschukzusammensetzungen, Verfahren zu deren Herstellung und deren Anwendung.
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
CA2114313A1 (en) Bpc peptides, their preparation and use
AU6408898A (en) Antimicrobial compositions, their preparation and use
HUP9900365A3 (en) N-aryl-1,2,4-triazolin-5-on derivatives, preparation and use thereof, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients
AU6732598A (en) A biocompatible composition, methods for its preparation and uses thereof
AU5728994A (en) Cytoprotective, biocompatible, retrievable macrocapsules
AU2736895A (en) Novel chemical compound, its preparation and use as a drug
AU7569796A (en) Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds.
AU1945495A (en) Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
AU4806497A (en) Glyoxylic compound comprising one or more active ingredient
AU7642894A (en) Low friction, hydrophilic, biocompatible compositions
AU3189197A (en) Agricultural compositions containing glycolic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 14/61 A, 7A 61K 38/27 B, 7A 61K 9/52 B, 7A 61K 9/16 B, 7A 61P 5/06 B

17P Request for examination filed

Effective date: 20010228

AKX Designation fees paid

Free format text: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010822

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

18D Application deemed to be withdrawn

Effective date: 20040421